Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Seasilver settlement

This article was originally published in The Tan Sheet

Executive Summary

Supplement marketers Americaloe and Seasilver will pay $4.5 mil. in consumer redress and will destroy $5.3 mil. worth of misbranded products as part of a settlement for the dietary supplement Seasilver, FTC announces March 17. The Carlsbad, Calif.-based companies are barred from making false or unsubstantiated claims for any supplement, food or drug and will pay only $3 mil. of the $120 mil. judgement owed due to "their demonstrated inability to pay more," FTC says. The complaint filed in June pointed to claims the product cured cancer and caused rapid, permanent weight loss without dieting (1"The Tan Sheet" June 23, 2003, p. 14)...

You may also be interested in...



Seasilver Seized By U.S. Marshals; FDA/FTC Challenge Companies In Court

U.S. Marshals seized 132,480 bottles of Seasilver liquid dietary supplement from Seasilver USA's San Diego headquarters June 17 at FDA's request

J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Topics

UsernamePublicRestriction

Register

PS096613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel